Fargeot P - Search Results

1

[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].

Coudert B, De Gislain C, Beltramo JL, Guigues B, Mayer F, Bruchon Y, Riedinger JM, Fargeot P, Dumas M, Guerrin J. Coudert B, et al. Among authors: fargeot p. Bull Cancer. 1996 Oct;83(10):847-52. Bull Cancer. 1996. PMID: 8952635 French.

2

[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].

Riedinger JM, Barillot I, Coudert B, Fargeot P, Berriolo-Riedinger A, Guerrin J. Riedinger JM, et al. Among authors: fargeot p. Bull Cancer. 1996 Aug;83(8):654-63. Bull Cancer. 1996. PMID: 8869046 French.

3

[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].

Riedinger JM, Coudert B, Barillot I, Buffenoir G, Mayer F, Fargeot P, Cuisenier J, Guerrin J. Riedinger JM, et al. Among authors: fargeot p. Bull Cancer. 1997 Sep;84(9):855-60. Bull Cancer. 1997. PMID: 9435806 French.

4

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.

Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B. Molucon-Chabrot C, et al. Among authors: fargeot p. Anticancer Drugs. 2006 Nov;17(10):1211-7. doi: 10.1097/01.cad.0000236309.66080.3b. Anticancer Drugs. 2006. PMID: 17075321 Clinical Trial.

5

MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.

Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C, Brunet-Lecomte P, Fargeot P. Lizard-Nacol S, et al. Among authors: fargeot p. Anticancer Res. 1999 Jul-Aug;19(4C):3575-81. Anticancer Res. 1999. PMID: 10629655

6

Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer.

Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P, Lizard-Nacol S. Arnal M, et al. Among authors: fargeot p. Breast Cancer Res Treat. 2000 May;61(1):13-20. doi: 10.1023/a:1006449931921. Breast Cancer Res Treat. 2000. PMID: 10930086

7

[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles].

Riedinger JM, Eche N, Basuyau JP, Daver A, Touzery C, Mayer F, Coudert B, Fargeot P, Chauffert B, de Gislain C, Zanetta S. Riedinger JM, et al. Among authors: fargeot p. Ann Biol Clin (Paris). 2002 Mar-Apr;60(2):183-91. Ann Biol Clin (Paris). 2002. PMID: 11937443 Free article. French.

8

[Course of blood creatinine during repeated injections of cisplatin. Influence of drug combinations].

de Gislain C, Dumas M, d'Athis P, Chapuis T, Mayer F, Fargeot P, Guerrin J, Escousse A. de Gislain C, et al. Among authors: fargeot p. Therapie. 1990 Sep-Oct;45(5):423-7. Therapie. 1990. PMID: 2260036 French.

9

[Role of chemotherapy in adjuvant treatment of breast cancer: modulation of the immune status].

Fargeot P, Guerrin J. Fargeot P, et al. Bull Cancer. 1984;71(4):346-53. Bull Cancer. 1984. PMID: 6388673 Clinical Trial. French.

10

Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.

Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P. Lizard-Nacol S, et al. Among authors: fargeot p. Breast Cancer Res. 1999;1(1):81-7. doi: 10.1186/bcr17. Epub 1999 Sep 1. Breast Cancer Res. 1999. PMID: 11056682 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters